Park J, Han JK, Kang J, et al. - In this study including 6,690 patients from the Grand-DES registry (a patient-level pooled registry), researchers determined the impact of β-blockers in acute coronary syndrome (ACS) following percutaneous coronary intervention. They evaluated the 3-year cumulative risk of all-cause mortality, cardiac death, and myocardial infarction. Findings showed that better clinical outcomes were achieved in correlation with β-blocker therapy in patients suffering from ACS, especially with medium-dose and vasodilating β-blockers.